Clinical trial · Interventional
Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer
Phase 2 Study of Aspirin Plus Exemestane Comparing With Exemestane Alone in the Adjuvant Treatment of Postmenopausal Breast Cancer
NCT01431053CI-TRIAL-00009706unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase II study to assess efficacy/safety of Exemestane with or without Aspirin as the adjuvant treatment in postmenopausal breast cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| aspirin | Drug | Aspirin | ALIAS |
| Exemestane | Drug | Exemestane | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Exemestane + Aspirin
- interventionNames
- Drug: aspirin
- Drug: Exemestane
- type
- ACTIVE_COMPARATOR
- label
- Exemestane
- interventionNames
- Drug: Exemestane
Primary outcomes (1)
- measure
- Quality of Life
- timeFrame
- 4 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 50 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Breast cancer after surgery postmenopausal Exclusion Criteria: * contraindication of aspirin
References
Publications (0)
Data not yet available
No reference posted for this study.